Pharmaron | Pharmaron API Commercial Synthesis Coventry (US)

The Pharmaron Coventry site, located in Rhode Island, USA, was acquired by Pharmaron in 2022, further expanding the company's global API development and manufacturing capabilities.

The FDA-approved facility is equipped with reactors ranging from 50 L to 8,000 L and supports batch production from a few grams to several hundred kilograms, covering the full development lifecycle from clinical phases through commercial manufacturing.

The site comprises a process research and development (PR&D) and pilot plant building, together with a commercial-scale manufacturing building, providing a total reactor capacity of 76,000 L.

Coventry features large-scale hydrogenation capabilities and is DEA-approved to manufacture controlled substances across Schedules I–V, supporting the production of highly specialized APIs.

As part of Pharmaron's integrated global network, the site also supports the company's hybrid China–US manufacturing model, where advanced intermediates are produced in China and transferred to Coventry for final API manufacturing. This approach delivers a resilient, flexible supply chain while maintaining cost efficiency.